Alembic Pharmaceuticals Limited has announced the schedule for its post-results conference call to discuss Q4FY26 quarterly and FY26 annual audited financial results. The pharmaceutical company informed stock exchanges on April 29, 2026 about the upcoming investor interaction scheduled for Friday, May 15, 2026.

Conference Call Details

The conference call is scheduled exclusively for analysts and institutional investors and will commence at 5:00 PM IST on Friday, May 15, 2026. The session will focus on discussing the company's Q4FY26 quarterly results and FY26 annual audited financial results.

Management Participation

The company's senior management team will represent Alembic Pharmaceuticals during the conference call. The management team includes key executives who will provide insights into the company's financial performance and business developments.

Participation Options

Alembic Pharmaceuticals has provided two convenient options for participants to join the conference call. The first option involves a Diamond Pass registration system that eliminates waiting time for operator assistance. Participants can register through the provided link and will receive dial-in numbers, passcode, and pin via email.

The second option offers traditional conference dial-in access with multiple contact numbers:

Contact Information

For additional information regarding the conference call, participants can contact Mr. Ajay Kumar Desai at phone numbers +91 22 66953681 or 7045504460, or via email at ajay.desai@alembic.co.in . The company secretary Manisha Saraf signed the official communication to the stock exchanges on April 29, 2026.

Alembic pharmaceuticals Limited has announced the sad demise of Mr. Saibal Mukherjee, Resident Director (Delhi Office), who passed away on 26th April, 2026. The pharmaceutical company filed the mandatory disclosure with BSE and NSE on 27th April, 2026, under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Senior Management Loss

Mr. Saibal Mukherjee had been serving as Resident Director at the company's Delhi Office and was considered an integral part of the organization. He joined Alembic Pharmaceuticals in 2014 and had been with the company for over a decade at the time of his passing.

The company described his demise as sudden and unexpected, stating it would be an irreparable loss to the organization. All directors and employees have conveyed deep sympathy, sorrow, and condolences to his family during this difficult time.

Regulatory Compliance Details

The disclosure was made in compliance with SEBI regulations and included the required details as per Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated 30th January 2026. The formal communication was signed by Company Secretary Manisha Saraf.

Corporate Impact

The loss of a senior management personnel represents a significant organizational change for Alembic Pharmaceuticals. Mr. Mukherjee's role as Resident Director for the Delhi Office made him a key figure in the company's operations in the national capital region.

The company has fulfilled its regulatory obligations by promptly informing the stock exchanges about this material change in senior management personnel, ensuring transparency with stakeholders and compliance with listing requirements.